Enanta Pharmaceuticals (ENTA) Stock Overview
A biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ENTA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Enanta Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.70 |
| 52 Week High | US$17.15 |
| 52 Week Low | US$6.44 |
| Beta | 0.97 |
| 1 Month Change | 17.09% |
| 3 Month Change | -2.91% |
| 1 Year Change | 108.84% |
| 3 Year Change | -28.72% |
| 5 Year Change | -67.23% |
| Change since IPO | -20.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| ENTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.3% | 0.02% | 0.6% |
| 1Y | 108.8% | 36.1% | 19.5% |
Return vs Industry: ENTA exceeded the US Biotechs industry which returned 36.1% over the past year.
Return vs Market: ENTA exceeded the US Market which returned 19.5% over the past year.
Price Volatility
| ENTA volatility | |
|---|---|
| ENTA Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ENTA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ENTA's weekly volatility has decreased from 15% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 120 | Jay Luly | www.enanta.com |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
Enanta Pharmaceuticals, Inc. Fundamentals Summary
| ENTA fundamental statistics | |
|---|---|
| Market cap | US$414.37m |
| Earnings (TTM) | -US$61.98m |
| Revenue (TTM) | US$69.21m |
Is ENTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENTA income statement (TTM) | |
|---|---|
| Revenue | US$69.21m |
| Cost of Revenue | US$0 |
| Gross Profit | US$69.21m |
| Other Expenses | US$131.20m |
| Earnings | -US$61.98m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 10, 2026
| Earnings per share (EPS) | -2.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -89.56% |
| Debt/Equity Ratio | 111.6% |
How did ENTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 22:28 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enanta Pharmaceuticals, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Geoffrey Meacham | Barclays |
| Patrick Trucchio | Berenberg |